Literature DB >> 21576079

Intra-individual stability over time of standardized anti-Mullerian hormone in FMR1 premutation carriers.

M A Spath1, T B Feuth, E G Allen, A P T Smits, H G Yntema, A Geurts van Kessel, D D M Braat, S L Sherman, C M G Thomas.   

Abstract

BACKGROUND: Carriers of a premutation (CGG repeat length 55-200) in the fragile X mental retardation (FMR1) gene are at risk for primary ovarian insufficiency (FXPOI). The anti-Müllerian hormone (AMH) level acts as a useful marker of ovarian follicle reserve and, thus, may serve to predict when this ovarian reserve becomes too low to sustain ovarian function. We investigated the intra-individual variation of AMH levels over time for premutation carriers compared with non-carriers.
METHODS: We determined AMH levels in blood samples from 240 women ascertained through fragile X families, of which 127 were premutation carriers and 113 were non-carriers. Linear mixed models were used to assess the effect of age and premutation status on AMH levels and to determine a modeled AMH value. The stability over time of the deviation of observed AMH levels from modeled levels, referred to as standardized AMH values, was assessed through correlation coefficients of 41 longitudinal samples.
RESULTS: At all ages, premutation carriers exhibited lower AMH levels. For all women, AMH was found to decrease by 10% per year. The added effect of having a premutation decreased AMH levels by 54%. The deviation of an individual's AMH level from the modeled value showed a reasonable intra-individual correlation. The Pearson correlation coefficient of two samples taken at different ages was 0.36 (P = 0.05) for non-carriers and 0.69 (P = 0.01) for carriers.
CONCLUSIONS: We developed a unique standardized AMH value, taking FMR1 premutation status and the subject's age into account, which appears to be stable over time and may serve as a predictor for FXPOI after further longitudinal assessment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576079      PMCID: PMC3137386          DOI: 10.1093/humrep/der146

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  41 in total

1.  Anti-Müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation.

Authors:  Wouter J K Hehenkamp; Caspar W N Looman; Axel P N Themmen; Frank H de Jong; E R Te Velde; Frank J M Broekmans
Journal:  J Clin Endocrinol Metab       Date:  2006-06-27       Impact factor: 5.958

2.  Nonlinear association between CGG repeat number and age of menopause in FMR1 premutation carriers.

Authors:  Sarah Ennis; Daniel Ward; Anna Murray
Journal:  Eur J Hum Genet       Date:  2006-02       Impact factor: 4.246

3.  Genetic counseling for fragile x syndrome: updated recommendations of the national society of genetic counselors.

Authors:  Allyn McConkie-Rosell; Brenda Finucane; Amy Cronister; Liane Abrams; Robin L Bennett; Barbara J Pettersen
Journal:  J Genet Couns       Date:  2005-08       Impact factor: 2.537

4.  Anti-mullerian hormone as a marker of ovarian reserve.

Authors:  Kelton P Tremellen; Michele Kolo; Alan Gilmore; Dharmawijaya N Lekamge
Journal:  Aust N Z J Obstet Gynaecol       Date:  2005-02       Impact factor: 2.100

5.  Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study.

Authors:  Ilse A J van Rooij; Frank J M Broekmans; Gabrielle J Scheffer; Caspar W N Looman; J Dik F Habbema; Frank H de Jong; Bart J C M Fauser; Axel P N Themmen; Egbert R te Velde
Journal:  Fertil Steril       Date:  2005-04       Impact factor: 7.329

6.  Serum anti-Mullerian hormone throughout the human menstrual cycle.

Authors:  A La Marca; G Stabile; A Carducci Artenisio; A Volpe
Journal:  Hum Reprod       Date:  2006-08-21       Impact factor: 6.918

7.  Serum concentrations of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women.

Authors:  A Murray; J Webb; F MacSwiney; E L Shipley; N E Morton; G S Conway
Journal:  Hum Reprod       Date:  1999-05       Impact factor: 6.918

8.  Association of FMR1 repeat size with ovarian dysfunction.

Authors:  A K Sullivan; M Marcus; M P Epstein; E G Allen; A E Anido; J J Paquin; M Yadav-Shah; S L Sherman
Journal:  Hum Reprod       Date:  2004-12-17       Impact factor: 6.918

9.  Anti-Müllerian hormone levels during hormonal contraception in women with polycystic ovary syndrome.

Authors:  Asli Somunkiran; Tevfik Yavuz; Oguz Yucel; Ismail Ozdemir
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2007-03-01       Impact factor: 2.435

10.  Examination of reproductive aging milestones among women who carry the FMR1 premutation.

Authors:  E G Allen; A K Sullivan; M Marcus; C Small; C Dominguez; M P Epstein; K Charen; W He; K C Taylor; S L Sherman
Journal:  Hum Reprod       Date:  2007-06-22       Impact factor: 6.918

View more
  19 in total

1.  Trisomic pregnancy and intermediate CGG repeat length at the FMR1 locus.

Authors:  J Kline; A Kinney; S Brown; B Levin; K Oppenheimer; D Warburton
Journal:  Hum Reprod       Date:  2012-04-06       Impact factor: 6.918

2.  Improving Health Education for Women Who Carry an FMR1 Premutation.

Authors:  Whitney Espinel; Krista Charen; Lillie Huddleston; Jeannie Visootsak; Stephanie Sherman
Journal:  J Genet Couns       Date:  2015-07-16       Impact factor: 2.537

3.  AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level.

Authors:  Lisa M Pastore; Timothy L McMurry; Christopher D Williams; Valerie L Baker; Steven L Young
Journal:  J Assist Reprod Genet       Date:  2014-06-18       Impact factor: 3.412

4.  Preimplantation genetic diagnosis versus prenatal diagnosis-decision-making among pregnant FMR1 premutation carriers.

Authors:  Lilach Marom Haham; Inbal Avrahami; Noam Domniz; Liat Ries-Levavi; Michal Berkenstadt; Raoul Orvieto; Yoram Cohen; Shai E Elizur
Journal:  J Assist Reprod Genet       Date:  2018-08-22       Impact factor: 3.412

Review 5.  Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families.

Authors:  Anne Wheeler; Melissa Raspa; Randi Hagerman; Marsha Mailick; Catharine Riley
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

6.  Reproductive and gynecologic care of women with fragile X primary ovarian insufficiency (FXPOI).

Authors:  Heather S Hipp; Krista H Charen; Jessica B Spencer; Emily G Allen; Stephanie L Sherman
Journal:  Menopause       Date:  2016-09       Impact factor: 2.953

Review 7.  Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency.

Authors:  Jenny A Visser; Izaäk Schipper; Joop S E Laven; Axel P N Themmen
Journal:  Nat Rev Endocrinol       Date:  2012-01-10       Impact factor: 43.330

8.  Intermediate CGG repeat length at the FMR1 locus is not associated with hormonal indicators of ovarian age.

Authors:  Jennie K Kline; Ann M Kinney; Bruce Levin; Stephen A Brown; Andrew G Hadd; Dorothy Warburton
Journal:  Menopause       Date:  2014-07       Impact factor: 2.953

Review 9.  Genomic markers of ovarian reserve.

Authors:  Michelle A Wood; Aleksandar Rajkovic
Journal:  Semin Reprod Med       Date:  2013-10-07       Impact factor: 1.303

10.  Are ovarian response and pregnancy rates similar in selected FMR1 premutated and mutated patients undergoing preimplantation genetic testing?

Authors:  Noemie Ranisavljevic; Mathilde Hess; Christel Castelli; Marjolene Willems; Alice Ferrieres-Hoa; Anne Girardet; Tal Anahory
Journal:  J Assist Reprod Genet       Date:  2020-06-02       Impact factor: 3.412

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.